AcelRx Pharmaceuticals

AcelRx Pharmaceuticals EV/FCF

Delisted

The EV/FCF (Enterprise Value to Free Cash Flow) of AcelRx Pharmaceuticals (ACRX) as of Nov 3, 2026 is -0.22. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -0.12 — a change of 91.77% (lower).

EV/FCF

-0.22

YoY

91.77%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of AcelRx Pharmaceuticals is 2023 -0.22 . EV/FCF (Enterprise Value to Free Cash Flow) of AcelRx Pharmaceuticals was 2022 -0.12 . It decreases by 91.77% lower compared to the previous year.

The AcelRx Pharmaceuticals EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2016
1.35 USD
Jan 1, 2017
0.85 USD
Jan 1, 2018
2.68 USD
Jan 1, 2019
0.50 USD
Jan 1, 2020
0.19 USD
Jan 1, 2021
0.77 USD
Jan 1, 2022
-0.12 USD
Jan 1, 2023
-0.22 USD
The AcelRx Pharmaceuticals EV/FCF history
YEAREV/FCFYoY
-0.22+91.77%
-0.12-115.18%
0.77+310.88%
0.19-62.51%
0.50-81.32%
2.68+213.64%
0.85-36.78%
1.35-63.50%
3.70+297.88%
0.93—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AcelRx Pharmaceuticals Stock analysis

What does AcelRx Pharmaceuticals do? AcelRx Pharmaceuticals Inc. is a California-based company specializing in the manufacturing of pain relief medications. The company was founded in 2005 and has since become an innovator in the development of pain medications. AcelRx's business model involves selling its patented products to hospitals and other healthcare facilities, and it is currently expanding into the global market. The company focuses on developing pain medications for emergency medicine and palliative care, with a particular emphasis on delivering medications through sprays or injections for fast-acting relief. AcelRx offers products such as Zalviso, a pain reliever based on Fentanyl nasal sprays used for post-operative pain, and Dsuvia, a sublingual tablet containing the active ingredient Sufentanil for severe pain. The FDA has approved Dsuvia as safe and effective. AcelRx has also entered partnerships with other pharmaceutical companies, such as Grünenthal and Chinese company R-Pharm, to bring its products to the international market. The company is committed to investing in research and development for innovative pain relief solutions, including a new research program targeting the development of medications for neuropathic pain. AcelRx Pharmaceuticals is a positive example of how modern pharmaceuticals can improve healthcare and quality of life. The company has demonstrated its potential through dedication and continuous research and development, and it is likely to make even greater contributions in the future. AcelRx Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AcelRx Pharmaceuticals stock

EV/FCF (Enterprise Value to Free Cash Flow) of AcelRx Pharmaceuticals is -0.22 in 2023.

EV/FCF (Enterprise Value to Free Cash Flow) of AcelRx Pharmaceuticals changed from -0.12 to -0.22, representing a 91.77% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) AcelRx Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s AcelRx Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — AcelRx Pharmaceuticals

All Key Metrics — AcelRx Pharmaceuticals